Visit Quest Diagnostics booth #2002 | October 17–21 | Berlin, Germany
Join us at the 2025 European Society for Medical Oncology (ESMO) Congress as we share how Haystack MRD, our tumor-informed ctDNA test, is helping redefine the role of minimal residual disease testing in clinical practice and oncology drug development.
Why visit us?
At Quest Diagnostics booth #2002, you’ll learn how Haystack MRD helps enable
- Confident adjuvant therapy decisions with data-driven insights
- Earlier recurrence detection compared to traditional methods
- Precise treatment response monitoring throughout the patient journey
- Efficient patient stratification and enrichment in oncology clinical trials
Whether you’re a clinician navigating complex treatment decisions or a biopharma leader driving trial innovation, Haystack MRD brings sensitivity, specificity, and scale to solid tumor treatment monitoring.
Let’s connect in Berlin
About Haystack MRD
Next-generation ctDNA detection with exceptional sensitivity and specificity for precise MRD reporting
Haystack MRD is a tumor-informed ctDNA detection test for measurement of residual and recurrent disease in solid tumor settings. Exceptional sensitivity and specificity translate to better MRD detection for greater confidence when making key clinical decisions.
Purpose-built MRD technology developed by pioneers of cancer research
Haystack MRD was designed specifically for ultrasensitive ctDNA detection when testing for residual or recurrent disease. Better sensitivity and specificity than traditional methods means that patients are more likely to receive the right treatment at the right time, which can significantly improve outcomes and quality of life for patients who have been diagnosed with cancer.
Experience the power of Quest
Haystack MRD leverages Quest’s credentialed staff, labs, logistics, service, reporting, and technology for a streamlined testing experience. Plus, from early detection screening to diagnosis, monitoring, and beyond, Quest offers routine to advanced testing for every stage of cancer. Experience the efficiency of working with a single lab to improve the quality and speed of cancer care.
